Our laboratory has investigated replicating adenovirus-human sodium iodide symporter (Ad-hNIS) vectors in a combinatorial oncolytic approach known as radiovirotherapy. However, hNIS-mediated iodide sequestration requires an intact cell membrane, and the enhancement of infectivity may alter the radioiodide accumulation in vivo. To assess these effects, we constructed Ad-NIS vectors expressing NIS from the major late promoter. Viral tropism was altered using a hybrid Ad5/3 fiber, and rates of viral spread altered through expression of the Ad death protein (ADP). The hybrid 5/3 fiber enhanced Ad-mediated cytolysis and radioisotope uptake in vitro. Replicating ADP-lacking viral vectors showed levels of uptake similar to non-replicating vectors that declined as cells lysed. ADP expression enhanced the rate of cell lysis and viral release, but reduced the peak and duration of radioiodide uptake. SPECT-computed tomography imaging showed the Ad5/3-noADP-hNIS vector induced significantly more isotope uptake than other vector structures, indicating that viral spread may not always make up for the reduced NIS expression as in our work with prostate cancer. These results indicate that replicating, infectivity-enhanced Ad-NIS vectors provide superior overall efficacy, but also indicate that the effect of replication speed requires tumor and model-specific testing.
INTRODUCTION
Cancer is the second leading cause of death worldwide, 1 accounting for an estimated 7.5 million deaths despite advances in surgical, radiotherapeutic and chemotherapeutic treatments. Billions of dollars have been invested to generate novel and effective cancer therapies, including combinatorial treatments. These therapies are designed to induce tumor lysis by multiple pathways, to address the variety of mutations that may confer resistance to a single therapeutic agent. 2 Our prior work has explored a multimodal approach to cancer treatment through Adenovirus (Ad) vectors expressing the sodium iodide symporter (NIS). NIS-mediated radiotherapy is a decade-old treatment for thyroid cancer. 3 Native NIS expression induces uptake of radioactive isotopes of iodide, including the majority of metastatic deposits, allowing for non-invasive imaging and therapy. The NIS transgene has been functionally expressed in a wide variety of cell lines, [4] [5] [6] [7] [8] [9] allowing other cancer models to take advantage of NIS expression. This work has progressed to clinical trials of NIS-expressing vectors. [10] [11] [12] Replicating NIS-expressing vectors can combine 131 I treatment with oncolytic virotherapy for the multimodal treatment dubbed radiovirotherapy. 13 Replicating vectors induce tumor lysis and viral spread, potentially amplifying the effect of radioiodide therapy as more infected cells are available to take up radioiodide. This addresses the critical problem in oncolytic gene therapy of low tumor transduction efficiency.
14 Replicating Ad vectors can easily contain the NIS transgene in the E3 region. 6, 7 NIS-mediated radioisotope uptake can be used to correlate viral genome titers, and accurately determine sites of viral replication. 15, 16 However, radiovirotherapy is a complex system depending on many interdependent variables, including the rate of cell killing, viral production, the amount of time an infected cell expresses NIS before lysis 17 and the presence of an intact cell membrane for iodide concentration. Although vector modifications such as replication competency or fiber modification have been shown to improve virotherapy, little work comparing their effects on radioiodide uptake and therapy has been reported.
To examine the effects of vector modifications on a radiovirotherapy vector, we have produced Ad-NIS vectors bearing different vector structures and observed their effects on radioisotope uptake and oncolysis. One effect we examined was the rate of replication of Ad-NIS vectors. For this purpose, we generated replicating vectors that express NIS via the Ad major late promoter (MLP) and compared them to non-replicating vectors expressing NIS from a cytomegalovirus (CMV) promoter in the E1 region. The MLP is activated downstream of the E1 region and can robustly express transgenes in the E3 region. 18, 19 To further assess the effect of replication, we generated replicating vectors that express or lack the Ad death protein (ADP). ADP is responsible for hastening cell lysis after viral assembly is complete, and its inclusion or exclusion generates a quick-spreading or slowspreading vector, respectively. 20 In addition, we wished to examine the effect of altering viral tropism. Our vectors are based on Ad serotype 5, which uses the coxsackie-Ad receptor to enter host cells. As a result this protein is often downregulated or absent in advanced cancers, [21] [22] [23] [24] many groups have altered the tropism of Ad5 vectors via fiber modification. We investigated the usefulness of a hybrid Ad5 fiber containing the knob domain of Ad serotype 3, 25 which binds to desmoglein-2, 26 which continues to be expressed even as coxsackie-Ad receptor expression is lost. 27, 28 For this study, we generated nonspecific Ad vectors and tested them in the non-small cell lung carcinoma line A549. Six Ad vectors were generated, bearing permutations of the replicative speed and fiber modifications described above. We compare these six vectors' ability to induce cytolysis and radioisotope uptake and discuss their potential use as radiovirotherapy vectors.
MATERIALS AND METHODS

Cell lines
The non-small cell lung carcinoma cell line A549 and human embryonic kidney cell line HEK 293 were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured as described. 29 During cell culture experiments, media serum content was reduced to 2%.
Generation of viral vectors
The non-replicating Ad5-CMV-hNIS has been described previously. 5 For pAd5/3-CMV-hNIS, NIS was amplified by PCR from pcDNA3_hNIS with primers containing 5 0 KpnI and 3 0 XhoI restriction sites. KpnI/XhoI-digested gene product was ligated into KpnI/XhoI-restricted pShuttle-CMV, 30 generating pShuttle-CMV-hNIS. pShuttle CMV-hNIS was homologously recombined in BJ5183 bacteria to the backbone plasmid pMG553, which contains the chimeric fiber gene encoding the knob domain of Ad3, 31 generating pAd5/3-CMV-hNIS. For the replicating vector plasmids, NIS was amplified by PCR-amplification from pcDNA3_hNIS using primers containing a 5
0 XbaI site and a 3 0 SalI site. XbaI/SalI-digested gene product was ligated into XbaI/SalI-restricted pShuttleDE3ADPKanF2 or pShuttleDE3KanF2, generating pShuttle DE3hNIS-ADPKanF2 and pShuttle DE3-hNIS-KanF2. These shuttle vectors were homologously recombined with either pMG553 or pTG3602, a backbone plasmid containing the wildtype Ad5 genome. The recombinant plasmids were SwaI restricted and religated to remove Kan resistance, generating pAd5-hNIS, pAd5/3-hNIS, pAd5-ADP-hNIS and pAd5/3-ADP-hNIS. Each of the genomic vector plasmids described above were linearized by PmeI restriction, and transfected into 911 cells using Superfect transfection reagent (Qiagen, Venlo, The Netherlands) to generate the vectors.
Crystal violet staining assays of cytopathic effect A total of 50 000 cells per well were seeded in 24-well tissue culture plates and infected 24 h later at the indicated viral dose. Seven days postinfection, culture media was removed and cells were incubated in 10% formalin for 5 min. Formalin was aspirated and cells were incubated at room temperature in 1% crystal violet in 10% methanol for 20 min. Cells were then rinsed twice with distilled water and photographed with a CoolPix 5700 camera (Nikon, Tokyo, Japan).
Radioisotope uptake assays
In all, 10 5 cells per well were seeded in 12-well tissue culture plates, and infected as above. At the indicated time points, culture media was aspirated, rinsed, and replaced with 10 mM HEPES in Hank's balanced salt solution containing 0.1 mM NaI and 10 5 c.p.m. of 125 I. Control incubations included 0.1 mM KCLO 4 to confirm NIS-specific isotope uptake. Cells were incubated for 45 min at 37 1C, 5% CO 2 , followed by aspiration and rinsing in ice-cold Hank's balanced salt solution, then lysed in 1 M NaOH for 5 min with shaking. Radioactivity of lysates was measured using a Wizard 2 2470 Automatic Gamma Counter (PerkinElmer, Waltham, MA, USA).
Burst assays
In all, 10 6 cells were plated on 100 mm dishes were infected at multiplicity of infection 20 of virus, followed 4 h later by washing and replacement with 10 ml fresh media. At 48 and 96 h post-infection, media and adherent cells were collected separately and titered by plaque assay on HEK 293 cells. Total plaque-forming unit (PFU) from ADP-possessing vectors were compared with their ADP-lacking counterparts by t-test.
Animal studies
All experimental protocols were approved by and conducted under guidelines of the Mayo Foundation Institutional Animal Care and Use Committee. All animals were purchased from Harlan Laboratories (Indianapolis, IN, USA) and maintained in the animal barrier facilities of the Mayo Foundation. Mice were kept on an iodide-deficient diet supplemented with L-thyroxine (5 mg l À 1 ) in the drinking water to reduce thyroidal iodide uptake.
Subcutaneous tumor models In vivo radioisotope uptake measurement by SPECT-computed tomography Mice bearing tumor xenografts of 200-250 mm 3 were injected intratumorally with 10 9 PFU of the viral constructs described above (n ¼ 4 per group). At the given time points (measured in days post-virus injection), mice were injected intraperitoneally with 0.5 mCi of 99 Tc as sodium pertechnetate. Mice were then anesthetized by induction of 4% isofluorane using a Summit Medical Anesthesia Machine (Summit Medical Equipment, Bend, OR, USA), transferred to the examination bed of a Gamma Medica XSPECT System (Gamma Medica, Northridge, CA, USA), and kept under anesthesia by maintenance of 2% isofluorane through a nose cone. The SPECT scan was performed with a parallel-hole collimator, field of view of 12.5 cm, with resolution of 1-2 mm. Sixty-four projections, 10 s each, were acquired to create a three-dimensional isotope uptake map. The computed tomography scan was performed with a continuous circular orbit. In all 256 images were acquired at 80 kVp and 0.28 mA, 50 mm slice thickness, 43 mm resolution. Intratumoral radioisotope uptake was quantified using the PMOD Biomedical Image Quantification and Kinetic Modeling Software (PMOD Technologies, Zurich, Switzerland), and difference between mean uptakes was tested by a repeated-measures analysis of variance followed by Tukey's HSD test.
RESULTS
Viral vectors
We generated two sets of vectors that express either the wild-type Ad5 fiber or the hybrid Ad5/3 fiber. Each set contains a nonreplicating vector-expressing NIS from the CMV promoter, and replicating vectors that express NIS or NIS and ADP from the E3 region ( Figure 1) . Cytopathic effect of the Ad-NIS vectors Crystal violet stains of cells infected by one of the six vectors showed that increasing the rate of viral spread or incorporation of the hybrid fiber protein improved the speed of cytopathic effect in A549 cells (Figure 2) . The ADP-expressing vectors showed cytopathic effect at a 100-fold lower dose than their ADP-lacking counterparts, whereas the non-replicating vectors showed no appreciable cytopathic effect. Exchange of the wild-type Ad5 fiber with the hybrid fiber protein reduced the viral dose needed for cytopathic effect by 10-fold.
Radioiodide uptake assays The rate of viral spread and fiber proteins also affected the radioiodide uptake (Figure 3) . Infection by the viruses bearing the 5/3 hybrid fiber resulted in earlier peaks of 125 I uptake B2-fold greater than their Ad5 counterparts in all three replication profiles. In addition, the rate of viral spread also affected how infected cells concentrated radioiodide. With the non-replicating vectors, the amount of uptake observed was dose dependent, and sustained NIS expression was seen at all dose levels. With the replicating vectors, infection resulted in transient peaks of radioisotope uptake that fell after viral oncolysis began. Lowering the dose of administered virus delayed the peak of uptake. Infection with ADP-expressing vectors resulted in radioiodide uptake peaks of shorter magnitude and duration, correlating with the more effective viral oncolysis observed in the cytopathic effect assays above. Parallel experiments performed in the presence of 10 mM KCLO 4 showed minimal 125 I uptake, indicating the uptake was NIS specific (Supplementary Figure S1) .
Burst assays
Burst assays were performed with the replicating vectors to determine the potential effect of ADP and fiber modification on the production of viral progeny (Figure 4 ). Fiber modification did not appear to alter the titer or speed of viral release, suggesting that the difference in cytopathic effect is due to differences in viral access to receptor. ADP expression resulted in robust viral release 2 days post-infection, with viral bursts at 10 (Figure 4a) , and the viral bursts were only 10-50 PFU per cell. Titers of intracellular PFUs of all viruses ranged in the 10 8 -10 9 range 2 days post-infection, indicating the low extracellular titers for ADP-lacking vectors were primarily due to delays in viral release rather than reduced viral production (Figure 4b ). However, total viral progeny recovered at this time was B10-fold higher in the ADP-expressing vectors than the ADP-lacking vectors (Po0.01) (Figure 4c ).
In vivo radioisotope uptake Serial SPECT-computed tomography imaging of A549 xenografts injected with 10 9 PFU of vector was performed to assess radioisotope uptake in vivo, as well as to establish an optimal time point for therapeutic 131 I administration. Imaging revealed that the replicating vectors induced greater radioisotope uptake, but the improved rate of spread seen in the ADP-expressing vectors in vitro did not result in greater NIS expression over time ( Figure 5 ). Fiber modification further improved intratumoral radioisotope uptake, and a repeated-measures analysis of variance showed significant difference between the conditions. Tukey's HSD test revealed that Ad5/3-hNIS-infected tumors had significantly higher levels of 99 Tc uptake compared with all other conditions, and that Ad5-CMV-hNIS concentrated significantly less (Po0.05). As we have seen in previous studies, radioisotope uptake either peaked or plateaued at 4 days postinfection, indicating this as the optimal time point of isotope administration.
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DISCUSSION
The clinical utility of radiovirotherapy has been explored using various vectors and cancer models, [4] [5] [6] [7] [8] [9] 32 however, minimal direct comparison between vector structures has been reported to date. 7 This is a critical aspect of the radiovirotherapy paradigm, because overall efficacy relies on the most effective combination of viral oncolysis and isotope uptake. As both of these aspects have effects on both the tumor and each other, careful consideration of vector structure is required.
Addition of the 5/3 fiber to the Ad5-NIS vector structure improved both viral oncolysis and radioisotope uptake over its wild-type counterpart. Poor transduction by vectors bearing wildtype Ad5 fiber has been recorded in a variety of human cancers often because of the downregulation of coxsackie-Ad receptor in advanced cancer and the difficulty in accessing the tight junctions where it is expressed. [21] [22] [23] [24] This has led to modified fibers such as the Ad5/3 hybrid, which exploits the more readily expressed and available DSG-2 for more efficient transduction. [21] [22] [23] This hybrid fiber reduced the quantity of virus required to completely lyse wells of A549 cells by B10-fold while doubling the amount of radioisotope uptake detected in vitro. That fiber modification improved both arms of the radiovirotherapy paradigm was surprising, and opens the possibility that vector enhancements need not aid one aspect of radiovirotherapy at the expense of the other.
Replicating ADP-deficient vectors directly lysed A549 cells and induced peaks of uptake equal to or greater than their nonreplicating counterparts. Replicating vectors have been used to overcome a central barrier in oncolytic virotherapy: low initial tumor transduction rate, even if virus is administered intratumorally.
14 In addition to viral-mediated cytolysis, the replicating vectors robustly expressed NIS from the MLP. We have shown previously that tumor-specific promoter modifications of E1 resulted in tumor-specific replication in a prostate cancer model, although these vectors still expressed NIS in cell lines nonpermissive to replication. 6, 7 This suggested that NIS expression may also be made tumor specific, as the MLP is activated downstream of E1, and in turn lead to the generation of two conditionally replicating vectors that showed tumor-specific NIS expression when placed under MLP control. 33 Similar levels of peak iodide uptake were observed between the ADP-deficient and the replication-defective vectors in vitro, but differed in the duration of iodide uptake. Cells infected with the non-replicating vectors concentrated 125 I in a dose-dependent manner, and infection with replicating vectors resulted in peaks of uptake that faded as the cells were lysed by viral replication and were delayed by reducing the viral dose.
ADP expression enhanced the rate of viral spread, but reduced the peak and duration of radioiodide uptake in vitro, and total uptake in vivo. ADP expression reduced the viral dose needed to clear cells by B100-fold in the cytopathic effect assays, and coincides with the larger viral bursts released 2 days post-infection than ADP-lacking vectors. However, cells infected with ADPexpressing vectors showed both reduced magnitude and duration of isotope uptake. Taken together, these data indicate that cells 9 PFU of the indicated vector was injected intratumorally into xenograft A549 tumors in nude mice. At the indicated time points, mice were injected with 0.5 mCi 99 Tc, followed by imaging by SPECT-computed tomography 1 h later. Tukey's HSD showed Ad5/3-hNIS induced significantly greater, and Ad5-CMV-NIS significantly less, uptake than all other conditions (Po0.05). ADP, adenovirus death protein; AD, adenovirus; CMV, cytomegalovirus; CT, computed tomography; hNIS, human NIS; NIS, sodium iodide symporter.
infected by ADP-expressing Ads have less time available to accumulate radioiodide before cell lysis.
This effect was also observed in in vivo radioisotope uptake assays in A549 xenografts. All vectors showed relatively steady levels of radioisotope uptake throughout the study, regardless of the replicative profile of the vector. However, because Ad replication is necessarily cytolytic, sustained radioisotope uptake in tumors infected with replicating vectors indicates sustained replication and infection of A549 cells by progeny virions. That Ad5/3-hNIS induced the greatest levels of radioisotope uptake in this model indicates that the increased rate of viral spread observed in ADP-expressing vectors was not enough to offset the reduction in NIS activity observed in vitro. In addition to the more rapid lysis of infected cells reducing the timeframe of radioisotope uptake, this may also suggest other blocks to viral spread. The extracellular matrix of A549 cells has been shown to limit adenoviral spread, preventing progeny vectors from infecting any but the most immediately neighboring cells. 34 This may limit the gains of improved viral spread in this tumor model. This is an interesting finding, as our work in a prostate cancer cell line showed increased replication rate improving NIS expression and therapeutic benefit. 33 Extension of Ad-NIS radiovirotherapy to specific tumor types may require testing of ADP-lacking and -expressing vectors, as these tumor-specific factors may favor one vector structure over another.
Collectively, these results strongly support the utility of replicating 5/3 fiber vectors for Ad-NIS radiovirotherapy. Although the effects of ADP-amplified viral spread agree with previous findings in cell culture, radioimaging of xenograft A549 tumors indicates that increased viral replication does not necessarily increase transgene expression or activity. Given the variation in susceptibility to radio-or viro-therapeutic approaches, the tumor microenvironment and dissemination of tumor during progression, the effect of ADP expression will likely be variable from tumor to tumor and therefore must be examined on a tumorspecific model to better understand its influence on viral replication and to maximize Ad-NIS radiovirotherapy.
